down arrow

Co-Diagnostics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1897631057
USD
0.39
0.04 (10.43%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.340.41

52 Week

0.231.55
Valuation
Technical
Day's Volume

CASH

2.47 M

Shareholding (Mar 2025)

FII

0.28%

Held by 8 FIIs

DII

91.76%

Held by 9 DIIs

Promoter

0.00%

How big is Co-Diagnostics, Inc.?

22-Jun-2025

As of Jun 18, Co-Diagnostics, Inc. has a market capitalization of 9.13 million, with net sales of 0.57 million and a net profit of -35.86 million over the latest four quarters. The company reported shareholder's funds of 54.31 million and total assets of 71.19 million as of Dec 24.

Market Cap: As of Jun 18, Co-Diagnostics, Inc. has a market capitalization of 9.13 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Co-Diagnostics, Inc. reported net sales of 0.57 million and a net profit of -35.86 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 54.31 million and total assets of 71.19 million.

Read More

What does Co-Diagnostics, Inc. do?

22-Jun-2025

Co-Diagnostics, Inc. is a molecular diagnostics company focused on developing and marketing diagnostic technologies in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $0 million and a net loss of $8 million, with a market cap of $9.13 million.

Overview: Co-Diagnostics, Inc. is a molecular diagnostics company engaged in developing, manufacturing, and marketing diagnostics technology within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025). Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025). Market cap: USD 9.13 Million (Micro Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -0.43. Return on Equity: -74.83%. Price to Book: 0.19.<BR><BR>Contact Details: Address: 4049 S Highland Dr, SALT LAKE CITY UT: 84124-1664. Tel: 1 801 2789769. Website: http://codiagnostics.com/

Read More

Who are in the management team of Co-Diagnostics, Inc.?

22-Jun-2025

As of March 2022, the management team of Co-Diagnostics, Inc. includes Mr. Dwight Egan as Chairman, President, and CEO, along with independent directors Dr. Eugene Durenard, Mr. Edward Murphy, Mr. James Nelson, and Mr. Richard Serbin.

As of March 2022, the management team of Co-Diagnostics, Inc. includes Mr. Dwight Egan, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features several independent directors: Dr. Eugene Durenard, Mr. Edward Murphy, Mr. James Nelson, and Mr. Richard Serbin. <BR><BR>In summary, as of March 2022, the key members of the management team are Mr. Dwight Egan and the independent directors Dr. Eugene Durenard, Mr. Edward Murphy, Mr. James Nelson, and Mr. Richard Serbin.

Read More

Is Co-Diagnostics, Inc. overvalued or undervalued?

25-Jun-2025

As of March 27, 2025, Co-Diagnostics, Inc. is classified as "does not qualify" due to significant financial deterioration, negative ratios indicating overvaluation, and a year-to-date stock performance of -65.97%, underperforming the S&P 500's 2.44% return.

As of 27 March 2025, the valuation grade for Co-Diagnostics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued, given its negative financial ratios and lack of profitability. Key ratios include a price-to-book value of 0.21, an EV to EBITDA of 0.26, and an ROE of -74.83%, all highlighting the company's struggles.<BR><BR>In comparison to its peers, Co-Diagnostics, Inc. shows a less favorable position, with peers like MAIA Biotechnology, Inc. and MiNK Therapeutics, Inc. also classified as does not qualify but with varying EV to EBITDA ratios of -2.1328 and -3.4718, respectively. The company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -65.97% compared to the index's 2.44%. This further reinforces the conclusion that Co-Diagnostics, Inc. is overvalued in its current state.

Read More

Is Co-Diagnostics, Inc. technically bullish or bearish?

20-Sep-2025

As of June 2, 2025, Co-Diagnostics, Inc. shows a mildly bearish trend with mixed indicators, significantly underperforming the S&P 500 with a 1-year return of -66.41% and a 5-year return of -97.10%.

As of 2 June 2025, the technical trend for Co-Diagnostics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The weekly MACD and KST are mildly bullish, while the weekly RSI is bearish. The daily moving averages indicate a mildly bearish trend. Additionally, the Bollinger Bands show a bullish signal on the weekly timeframe but a mildly bearish signal on the monthly. The Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. <BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 over the longer term, with a 1-year return of -66.41% compared to the S&P 500's 17.14%, and a staggering 5-year return of -97.10% against the S&P 500's 96.61%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 13 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.30

stock-summary
Return on Equity

-87.49%

stock-summary
Price to Book

0.33

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.51%
0%
17.51%
6 Months
36.24%
0%
36.24%
1 Year
-56.08%
0%
-56.08%
2 Years
-70.04%
0%
-70.04%
3 Years
-87.53%
0%
-87.53%
4 Years
-95.37%
0%
-95.37%
5 Years
-96.43%
0%
-96.43%

Co-Diagnostics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Co-Diagnostics, Inc. technically bullish or bearish?

As of 2 June 2025, the technical trend for Co-Diagnostics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The weekly MACD and KST are mildly bullish, while the weekly RSI is bearish. The daily moving averages indicate a mildly bearish trend. Additionally, the Bollinger Bands show a bullish signal on the weekly timeframe but a mildly bearish signal on the monthly. The Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. In terms of performance, the stock has significantly underperformed the S&P 500 over the longer term, with a 1-year return of -66.41% compared to the S&P 500's 17.14%, and a staggering 5-year return of -97.10% against the S&P 500's 96.61%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-53.33%
EBIT Growth (5y)
-230.51%
EBIT to Interest (avg)
-3.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.03%
ROCE (avg)
83.78%
ROE (avg)
18.99%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.21
EV to EBIT
0.25
EV to EBITDA
0.26
EV to Capital Employed
-0.38
EV to Sales
-10.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-74.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 6 Schemes (7.96%)

Foreign Institutions

Held by 8 Foreign Institutions (0.28%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 100.00% vs 0.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -2.67% vs 31.82% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.80",
          "val2": "-8.30",
          "chgp": "6.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.70",
          "val2": "-7.50",
          "chgp": "-2.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-49,461.40%",
          "val2": "-170,096.80%",
          "chgp": "12,063.54%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -20.00% vs -97.08% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.52% vs -148.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "1.00",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.80",
          "val2": "-47.30",
          "chgp": "11.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-37.60",
          "val2": "-35.30",
          "chgp": "-6.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-56,134.70%",
          "val2": "-48,944.10%",
          "chgp": "-719.06%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.20
0.10
100.00%
Operating Profit (PBDIT) excl Other Income
-7.80
-8.30
6.02%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.70
-7.50
-2.67%
Operating Profit Margin (Excl OI)
-49,461.40%
-170,096.80%
12,063.54%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 100.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -2.67% vs 31.82% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.80
1.00
-20.00%
Operating Profit (PBDIT) excl Other Income
-41.80
-47.30
11.63%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-37.60
-35.30
-6.52%
Operating Profit Margin (Excl OI)
-56,134.70%
-48,944.10%
-719.06%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -20.00% vs -97.08% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -6.52% vs -148.59% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Co-Diagnostics, Inc. stock-summary
stock-summary
Co-Diagnostics, Inc.
Pharmaceuticals & Biotechnology
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
Company Coordinates stock-summary
Company Details
4049 S Highland Dr , SALT LAKE CITY UT : 84124-1664
stock-summary
Tel: 1 801 2789769
stock-summary
http://codiagnostics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."